TY - JOUR
T1 - Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever
AU - Wyber, Rosemary
AU - Boyd, Ben
AU - Colquhoun, Samantha
AU - Currie, Bart
AU - Engel, Mark Emmanuel
AU - Kado, Joseph
AU - Karthikeyan, Ganesan
AU - Sullivan, Mark
AU - Saxena, Anita
AU - Sheel, Meru
AU - Steer, Andrew
AU - Mucumbitsi, Joseph
AU - Zuhlke, Liesl
AU - Carapetis, Jonathan
PY - 2016/10
Y1 - 2016/10
N2 - Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.
AB - Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.
UR - http://www.scopus.com/inward/record.url?scp=84983604692&partnerID=8YFLogxK
U2 - 10.1007/s13346-016-0313-z
DO - 10.1007/s13346-016-0313-z
M3 - Article
C2 - 27465618
VL - 6
SP - 572
EP - 578
JO - Drug Delivery and Translational Research
JF - Drug Delivery and Translational Research
SN - 2190-393X
IS - 5
ER -